Responsibilities of Data Monitoring Committees: Consensus Recommendations

被引:8
作者
Bierer, Barbara E. [1 ,2 ,3 ,4 ]
Li, Rebecca [1 ,2 ,3 ,4 ]
Seltzer, Jonathan [5 ]
Sleeper, Lynn A. [6 ]
Frank, Elizabeth [7 ]
Knirsch, Charles [8 ]
Aldinger, Carmen E. [3 ,4 ]
Levine, Robert J. [9 ]
Massaro, Joe [10 ]
Shah, Amish [11 ]
Barnes, Mark [3 ,4 ,11 ]
Snapinn, Steven [12 ]
Wittes, Janet [13 ]
机构
[1] Brigham & Womens Hosp, Dept Med, Div Global Hlth Equ, 75 Francis St, Boston, MA 02115 USA
[2] Harvard Med Sch, Boston, MA USA
[3] Brigham & Womens Hosp, Multireg Clin Trials Ctr, 14 Story St,4th Floor, Cambridge, MA 02138 USA
[4] Harvard, 14 Story St,4th Floor, Cambridge, MA 02138 USA
[5] ACI Clin, Bala Cynwyd, PA USA
[6] Boston Childrens Hosp, Dept Cardiol, Boston, MA USA
[7] Dana Farber Canc Inst, Boston, MA 02115 USA
[8] Pfizer, New York, NY USA
[9] Yale Univ, New Haven, CT USA
[10] Boston Univ, Boston, MA 02215 USA
[11] Ropes & Gray, Boston, MA USA
[12] Amgen Inc, Thousand Oaks, CA USA
[13] Stat Collaborat Inc, Washington, DC USA
关键词
safety data; clinical trials; oversight of clinical trials; human subject safety; multi-site clinical trials; Data Monitoring Committees;
D O I
10.1177/2168479016646812
中图分类号
R-058 [];
学科分类号
摘要
Background: A data monitoring committee (DMC) has special responsibilities for protecting the safety of clinical trial participants. Few guidance documents are available that address the operations and mechanics of establishing, serving on, or reporting to a DMC. This article provides a practical guide to sponsors, institutions, and individuals responsible for, or serving on, a DMC. Methods: A workgroup of professionals from academia and not-for-profit and commercial organizations that included investigators, statisticians, patient advocates, and ethicists met to define the essential elements of planning, coordinating, and populating a DMC. All members of the group have formed, served on, advised, or worked with DMCs. Results: The group outlined the objectives and mechanics of running a DMC, including operational and practical considerations, membership characteristics, roles, members' liability, and indemnification. Further, it delineated the roles and responsibilities of each DMC member. Conclusions: The group recommended practices for each phase of the DMC process from inception through execution of a clinical trial, with appropriate considerations for confidentiality. The group's practical guidance should assist in comprehensive oversight of appropriate clinical trials and should help DMC members execute their obligations with greater assurance.
引用
收藏
页码:648 / 659
页数:12
相关论文
共 8 条
[1]
DeMets D.L., 2006, DATA MONITORING CLIN
[2]
DeMets David L, 2004, Clin Trials, V1, P525, DOI 10.1191/1740774504cn54oa
[3]
Ellenberg S., 2002, DATA MONITORING COMM
[4]
Ethical and Scientific Implications of the Globalization of Clinical Research [J].
Glickman, Seth W. ;
McHutchison, John G. ;
Peterson, Eric D. ;
Cairns, Charles B. ;
Harrington, Robert A. ;
Califf, Robert M. ;
Schulman, Kevin A. .
NEW ENGLAND JOURNAL OF MEDICINE, 2009, 360 (08) :816-823
[5]
US Food and Drug Administration, SAF ASS INV NEW DRUG
[6]
US Food and Drug Administration, 2006, GUID CLIN TRIAL SPON
[7]
BEHIND CLOSED DOORS - THE DATA MONITORING BOARD IN RANDOMIZED CLINICAL-TRIALS [J].
WITTES, J .
STATISTICS IN MEDICINE, 1993, 12 (5-6) :419-424
[8]
On independent data monitoring committees in oncology clinical trials [J].
Wittes, Janet ;
Schactman, Mark .
CHINESE CLINICAL ONCOLOGY, 2014, 3 (03)